Newsquawk Logo

Bayer (BAYN GY) files a lawsuit against Johnson & Johnson (JNJ) and Janssen Biotech; Says J&J claims on NUBEQUA are deeply flawed and are intentionally aimed at boosting sales of ERLEADA, with Bayer seeking injunction and damages

Bayer's lawsuit against Johnson & Johnson highlights significant tensions in the pharmaceutical sector, particularly regarding the competitive dynamics between their products, NUBEQUA and ERLEADA.

Newsquawk StaffPublished On the live feed at — 6 more headlines followed before this page went public
Newsquawk headlinesUTC

EU's Kallas said EU did not reach an agreement on Russian sanctions package

US Dallas Fed Manufacturing Index (Feb) 0.2 (Prev. -1.2)

Bayer (BAYN GY) files a lawsuit against Johnson & Johnson (JNJ) and Janssen Biotech; Says J&J claims on NUBEQUA are deeply flawed and are intentionally aimed at boosting sales of ERLEADA, with Bayer seeking injunction and damages

"A 10% tariff will be imposed on EU imports into the US following the recent tariff ruling by the US Supreme Court", dpa reports citing a White House Official [Desk awaiting clarity] [POST HAS BEEN SINCE DELETE]

Iran's Deputy Foreign Minister says there's an opportunity to resolve differences through dialogue, Al Jazeera reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

This legal action could impact both companies' reputations and sales strategies, while raising questions about market positions and potential regulatory responses, especially if Bayer seeks damages and an injunction, which may limit J&J's marketing practices.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.